Score Overview
Explore the 2021 public Archive ranking →
Where Ionis Pharmaceuticals Inc has ranked, year by year
Showing 20 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- IONS
2012: 96.1% · 2021: 75.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 45.57 | — |
1 Year2025-09-26 | $ 64.09 | -28.90% |
5 Years2021-09-28 | $ 34.36 | 32.63% |
10 Years2016-09-28 | $ 36.20 | 25.88% |
20 Years2006-09-28 | $ 7.49 | 6x |
30 Years1996-09-27 | $ 14.41 | 216.29% |
All Time1991-05-17 | $ 9.22 | 394.21% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1991-05-17 |
|---|---|---|---|---|---|---|---|
| Price | $ 45.57 | $ 64.09 | $ 34.36 | $ 36.20 | $ 7.49 | $ 14.41 | $ 9.22 |
| Return | — | -28.90% | 32.63% | 25.88% | 6x | 216.29% | 394.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 873M | -$ 564M | $ 2.05B |
| 2025 | $ 944M | -$ 381M | $ 2.67B |
| 2024 | $ 705M | -$ 453M | $ 2.29B |
| 2023 | $ 787M | -$ 366M | $ 2.33B |
| 2022 | $ 587M | -$ 269M | $ 1.99B |
| 2021 | $ 810M | -$ 28M | $ 2.11B |
| 2020 | $ 729M | -$ 487M | $ 1.89B |
| 2019 | $ 1.12B | $ 294M | $ 2.50B |
| 2018 | $ 599M | $ 273M | $ 2.08B |
| 2017 | $ 514M | $ 1.02B | |
| 2016 | $ 346M | -$ 86M | $ 667M |
| 2015 | $ 283M | -$ 88M | $ 803M |
| 2014 | $ 214M | -$ 38M | $ 810M |
| 2013 | $ 147M | -$ 60M | $ 708M |
| 2012 | $ 102M | -$ 65M | $ 408M |
| 2011 | $ 99M | -$ 84M | $ 343M |
| 2010 | $ 108M | -$ 61M | $ 472M |
| 2009 | $ 121M | $ 155M | $ 574M |
| 2008 | $ 107M | -$ 18M | $ 490M |
| 2007 | $ 58M | -$ 10M | $ 193M |
| 2006 | $ 14M | -$ 45M | $ 193M |
| 2005 | $ 40M | -$ 72M | $ 94M |
| 2004 | $ 42M | -$ 142M | $ 103M |
| 2003 | $ 49M | -$ 94M | $ 215M |
| 2002 | $ 80M | -$ 72M | $ 289M |
| 2001 | $ 53M | -$ 73M | $ 312M |
| 2000 | $ 37M | -$ 53M | $ 127M |
| 1999 | $ 33M | -$ 59M | $ 52M |
| 1998 | $ 39M | -$ 43M | $ 27M |
| 1997 | $ 32M | -$ 31M | $ 38M |
| 1996 | $ 22M | -$ 26M | $ 37M |
| 1995 | $ 13M | -$ 23M | $ 46M |
| 1994 | $ 10M | -$ 18M | $ 12M |
| 1993 | $ 12M | -$ 19M | $ 33M |
| 1992 | $ 8M | -$ 19M | $ 16M |
| IPO1991 | $ 6M | -$ 8M | $ 21M |
Ionis Pharmaceuticals Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 40M to $ 944M and net income went from -$ 72M to -$ 381M. Revenue increased in 14 of those 20 years; net income in 10.
Across Ionis Pharmaceuticals Inc's full reported history, from 1991 to 2025, revenue grew from $ 6M to $ 944M and net income went from -$ 8M to -$ 381M. Revenue increased in 66% of the years measured; net income in 45%.
Ionis Pharmaceuticals Inc currently holds a 20-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.
Membership
Continue IONS’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
